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Summary
Peroxisome-biogenesis disorders (PBDs), including Zell-
weger syndrome (ZS), are autosomal recessive diseases
caused by a deficiency in peroxisome assembly as well
as by a malfunction of peroxisomes, among which 110
genotypes have been identified. We have isolated a hu-
man PEX16 cDNA (HsPEX16) by performing an ex-
pressed-sequence-tag homology search on a human
DNA database, by using yeast PEX16 from Yarrowia
lipolytica and then screening the human liver cDNA
library. This cDNA encodes a peroxisomal protein (a
peroxin Pex16p) made up of 336 amino acids. Among
13 peroxisome-deficiency complementation groups
(CGs), HsPEX16 expression morphologically and bio-
chemically restored peroxisome biogenesis only in fibro-
blasts from a CG-D patient with ZS in Japan (the same
group as CG-IX in the United States). Pex16p was lo-
calized to peroxisomes through expression study of ep-
itope-tagged Pex16p. One patient (PBDD-01) possessed
a homozygous, inactivating nonsense mutation, CrT at
position 526 in a codon (CGA) for 176Arg, that resulted
in a termination codon (TGA). This implies that the C-
terminal half is required for the biological function of
Pex16p. PBDD-01–derived PEX16 cDNA was defective
in peroxisome-restoring activity when expressed in the
patient’s fibroblasts. These results demonstrate that mu-
tation in PEX16 is the genetic cause of CG-D PBDs.
Received July 24, 1998; accepted September 22, 1998; electronically
published November 11, 1998.
Address for correspondence and reprints: Dr. Yukio Fujiki, De-
partment of Biology, Kyushu University Faculty of Science, 6-10-1
Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan. E-mail: yfujiscb
@mbox.nc.kyushu-u.ac.jp
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6306-0008$02.00
Introduction
Peroxisomes are present in a wide variety of eukaryotic
cells, from yeast to human, and function in various met-
abolic pathways, including b-oxidation of very–long-
chain fatty acids and the synthesis of ether lipids (van
den Bosch et al. 1992). Peroxisomal proteins, including
membrane proteins, are encoded by nuclear genes and
translated on free polyribosomes in the cytosol (Lazarow
and Fujiki 1985). Peroxisomes are formed by division
of preexisting peroxisomes after the import of newly
synthesized proteins (Lazarow and Fujiki 1985). Genetic
analysis of peroxisome-biogenesis–defective mutants of
yeast and mammalian cells has led to the identification
of a number of protein factors, termed “peroxins,” es-
sential for peroxisome assembly (Distel et al. 1996; Fu-
jiki 1997; Subramani 1997). The primary cause of per-
oxisome deficiency in a group of fatal genetic diseases,
the peroxisome-biogenesis disorders (PBDs), which in-
clude Zellweger syndrome (ZS), neonatal adrenoleu-
kodystrophy, and infantile Refsum disease, is a failure
in peroxisome assembly (Shimozawa et al. 1992a; La-
zarow and Moser 1995; Fujiki 1997; Subramani 1997).
Genetic heterogeneity making up 14 complementation
groups (CGs) has been identified in mammals through
the use of fibroblasts from patients with PBDs, including
rhizomelic chondrodysplasia punctata and peroxisome-
deficient Chinese hamster ovary (CHO) cell mutants
(Zoeller et al. 1989; Tsukamoto et al. 1990; Shimozawa
et al. 1992a; Moser et al. 1995; Poulos et al. 1995;
Okumoto et al. 1997; Tateishi et al. 1997; Tsukamoto
et al. 1997; Kinoshita et al. 1998; Otera et al. 1998;
Shimozawa et al. 1998a). Therefore, 114 genes are likely
involved in mammalian peroxisome biogenesis. We have
to date cloned PEX2 (formerly “PAF-1”; Tsukamoto et
al. 1991), PEX6 (Tsukamoto et al. 1995), PEX12 (Oku-
moto and Fujiki 1997; Okumoto et al. 1998b), and
PEX1 (Tamura et al. 1998) cDNAs by genetic pheno-
type-complementation assay of CHO cell mutants Z65,
ZP92, ZP109, and ZP107, respectively. Several human
orthologues of yeast peroxins have been isolated by
means of expressed-sequence-tag (EST) analysis of the
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human database, by use of yeast PEX genes (Subramani
1997; Abe et al. 1998; Okumoto et al. 1998a).
A nonsense mutation of the PEX2 gene encoding a
35-kD peroxisome integral membrane protein was iden-
tified, for the first time, to be the primary cause of ZS
in CG-F (the same group as CG-X in the United States
and CG-5 in Europe; Shimozawa et al. 1992b). Dys-
function and mutations of PEX5 encoding the PTS1 re-
ceptor were found in CG-II patients (Dodt et al. 1995;
Wiemer et al. 1995). PEX6 encoding a member of an
ATPase family was shown to be responsible for ZS in
CG-C (the same as CG-IV in the United States; Fukuda
et al. 1996; Yahraus et al. 1996). PEX12 and PEX1
were recently shown to be mutated in PBD patients in
CG-III (Chang et al. 1997; Okumoto and Fujiki 1997;
Okumoto et al. 1998b) and CG-I (Portsteffen et al. 1997;
Reuber et al. 1997; Tamura et al. 1998), respectively.
More recently, mutation of PEX10 was found to be the
genetic cause of ZS in CG-B (the same as CG-VII in the
United States; Okumoto et al. 1998a).
Herein we report how, by performing an EST ho-
mology search with Yarrowia lipolytica PEX16, we iso-
lated human PEX16 cDNA (HsPEX16) encoding a per-
oxin Pex16p. Peroxisome formation was reestablished
in peroxisome-deficient fibroblasts from a CG-D patient
(CG-IX in the United States) with PBD, by transfection
of HsPEX16. We identified a homozygous mutation that
inactivated PEX16 in this patient.
Material and Methods
Cell Lines
Skin-fibroblast cell lines from patients, including sev-
eral patients’ fibroblasts transformed with SV40, were
cultured in Dulbecco’s modified Eagle’s medium-high
glucose supplemented with 10% fetal calf serum, as de-
scribed elsewhere (Fukuda et al. 1996; Okumoto et al.
1998b). Fibroblasts from a CG-D patient (PBDD-01
[GM06231]) were purchased from the Human Genetic
Mutant Cell Repository (Yajima et al. 1992). CHO cells
were cultured as described elsewhere (Tsukamoto et al.
1990; Tsukamoto et al. 1991).
Cloning of Human PEX16
A GENETYX-MAC program (Software Develop-
ment) was used to perform PCR on the human liver
cDNA library in pCMVSPORT I (Gibco BRL; Tamura
et al. 1998) with sense primer HsPEX16.FL (5′-AC-
GAATTCCGCAGGATGGAGAAGCTGC-3′ [the poten-
tial initiation codon is underlined]) and antisense primer
HsPEX16.RL (5′-ATTGGATCCGGACAGCTCGTGC-
GAATCG-3′), containing nucleotide residues at posi-
tions 77–94 and 205–221, respectively, of the human
EST AA357684 that showed good homology (38%
identity) to YlPEX16 (Eitzen et al. 1997). The PCR
product was used as a probe to screen the human liver
cDNA library (Tamura et al. 1998). Two positive clones,
F6-7-18 and F6-7-39, were isolated from a subpool, F6-
7, and their nucleotide sequences were determined;
F6-7-39, made up of 1,171 bp, was termed “p-
CMVSPORT•HsPEX16” and contained a 1,008-bp
open reading frame (ORF) encoding a 336-amino-acid
polypeptide.
Transfection of HsPEX16
pCMVSPORT•HsPEX16 was transfected into PBD-
patient fibroblasts by a Gene Pulser II electroporator
(Bio-Rad) at a setting of 320 V/500 mF. Transfection to
CHO cell mutants was performed with Lipofectamine
(Gibco BRL) as recommended by the manufacturer
(Okumoto et al. 1998b; Tamura et al. 1998).
Morphological Analysis
Peroxisomes in human fibroblasts and in CHO cells
were visualized by indirect immunofluorescence micros-
copy, as described elsewhere (Shimozawa et al. 1992a).
The antibodies used were raised, in rabbit, to human
(Shimozawa et al. 1992b) and rat (Tsukamoto et al.
1990) catalase, to the 70-kD integral membrane protein
of peroxisomes (PMP70) of rat (Tsukamoto et al. 1990;
Kinoshita et al. 1998), and to the peroxisome-targeting
signal type 1 (PTS1) peptide (Otera et al. 1998). Antigen-
antibody complexes were detected by means of fluores-
cein isothiocyanate (FITC)–labeled sheep anti–rabbit im-
munoglobulin G antibody (Cappel), by a Carl Zeiss
Axioskop FL microscope.
Mutation Analysis
Poly(A) RNA was obtained from fibroblasts of a nor-
mal control and a CG-D patient (PBDD-01), with a
QuickPrep mRNA purification kit (Pharmacia Biotech).
Reverse transcription (RT)–PCR was performed with
poly(A) RNA (1 mg), oligo-dT primer (0.5 mg), and
Superscript II reverse transcriptase (Gibco BRL) in 50
ml of the reaction mixture. To amplify the full length of
the PEX16 ORF, PCR was performed with a pair of
human-specific PCR primers (50 pmol each), sense
16RTN (5′-GGAAGCTTGCCACCATGGAGAAGC-
TGCGGCTCCTGGGCCTCCGC-3′ [initiation codon
underlined]) and antisense 16RTC (5′-CCCACTAGTG-
AATTCAGCCCCAACTGTAGAAGTAGATTTTCTG-
3′ [termination codon underlined]), in 50 ml of the re-
action mixture, which contained template DNA (⅛ al-
iquot of the RT product), 100 mM of dNTP, and 2.5 U
of ExTaq DNA polymerase (Takara). Initial denatura-
tion was done at 96C for 45 s, followed by 25 cycles
of denaturation at 96C and annealing at 60C, for 45
s each, and extension at 72C for 90 s. PCR products
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Figure 1 Deduced amino acid sequence of HsPEX16 protein
from CG-D ZS patient PBDD-01 (Hs), in comparison with that of
Pex16p from Y. lipolytica (Yl). Broken lines (- - -) indicate a space.
Amino acids that are identical in HsPEX16 and YlPEX16 proteins
are shaded; hydrophobic segments are overlined. The arrowhead in-
dicates the position of the mutation in the patient. The GenBank ac-
cession number for HsPEX16 cDNA is AB016531.
were cleaved with HindIII and SpeI, cloned into the
HindIII/SpeI site of pBluescript II SK() (Gibco BRL),
and sequenced. The patient’s PEX16 cDNA was di-
gested with SalI and NotI and cloned into the SalI/NotI
site of pCMVSPORT. Transfection of fibroblasts was
done by electroporation.
Genomic DNA was prepared from cultured fibroblasts
(Fukuda et al. 1996), with a QIAamp tissue kit (Qiagen).
To investigate the zygosity of the PEX16R176Ter allele
in patient PBDD-01, PCR amplification of the sequence
between residues 471 and 697 was performed with the
genomic DNA and a pair of PEX16-specific primers (50
pmol each): sense 16GF (5 ′-CAGCCCTGGCAA-
CCATG-3′) and antisense 16GR (5′-GCAAGTGCAGC-
AGCGG-3′). Initial denaturation was performed at 96C
for 2 min, followed by 30 cycles of denaturation at 96C,
annealing at 55C, and extension at 72C, for 1 min
each. PCR products were extracted and sequenced
directly.
Expression of Epitope-Tagged Pex16p
Influenza virus hemagglutinin (HA)–epitope tagging
of the C-terminus of Pex16p was performed by PCR
with the forward primer HsPEX16F4 (5′-CCCTGCA-
CTCCAGG-3′, with the nucleotide sequence at positions
548–561 and A starting in the initiation codon as 1)
and the reverse primer HsPEX16HA (5′-CCCAAGCTT-
TCATGCATAATCGGGCACATCGTAGGGGTATGC-
ATAATCGGGCACATCGTAGGGGTAGCTAGCGCC-
CCAACTGTAGAAGTAGATTTTC-3′; tandem HA-tag
sequence underlined). The internal PstI-HindIII frag-
ment of the PCR product was cloned into the PstI/
HindIII site of pBluescript SK(-), to give pBluescript SK(-
)•HsPEX16-F4HA. The HsPEX16-HA expression plas-
mid was constructed by introducing the PstI-SalI frag-
ment of pBluescript SK(-)•HsPEX16-F4HA and the
NotI-PstI fragment of HsPEX16 into the NotI/SalI site
of the pUcD2Hyg vector (Okumoto et al. 1998b). HA-
tagged Pex16p expressed in cells was detected by means
of mouse monoclonal antibody to HA (Boehringer
Mannheim) and by FITC-labeled sheep anti–mouse IgG
secondary antibody (Amersham).
Other Methods
Nucleotide sequencing was performed according to
the dideoxy-chain termination method with a dye-ter-
minator DNA sequence kit (Applied Biosystems). Align-
ment was effected with the CLUSTAL W program
(EMBL).
Results and Discussion
Cloning of Human PEX16 cDNA
We identified several cDNA clones for the mammalian
orthologue of Y. lipolytica PEX16 (YlPEX16; Eitzen et
al. 1997), including the human ESTs AA357684 and
AA602247 and the mouse ESTs AA673100 and
W97828, by the EST-homology search method—that is,
BLAST search using the TBLASTN program (Altschul
et al. 1990). We then isolated two positive clones by
screening the human liver cDNA library with an
AA357684-derived probe (see Material and Methods);
one of the clones, F6-7-39, contained a 1,171-bp cDNA
with an ORF encoding a 336-amino-acid protein of
38,642 daltons (fig. 1). Homology analysis suggested
that this ORF was most likely to encode the human
orthologue of YlPEX16 (Eitzen et al. 1997). Therefore,
we termed this cDNA “HsPEX16.” The HsPEX16 pro-
tein, HsPex16p, was shorter than YlPex16p by 55 amino
acids in primary sequence, and the average amino acid
identity to YlPex16p was 24%. Moreover, no potential
N-glycosylation site was found in HsPex16p, but
YlPex16p was reported to be N-glycosylated, presum-
ably at position 272 (Titorenko and Rachubinski 1998).
PEX16 Restores Peroxisome Assembly in CG-D Patient
Fibroblasts
Catalase in fibroblasts was visualized by immunos-
taining with the anti–human catalase antibody (Shi-
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Figure 2 Complementation of peroxisomes in fibroblasts from a CG-D ZS patient. A, Transfection of HsPEX16 into fibroblasts from a
CG-D patient (PBDD-01) with ZS: fibroblasts from (a) a normal control, (b–d and f–h) PBDD-01, and (e) a CG-F patient with ZS (Shimozawa
et al. 1992b). PBDB-01 fibroblasts were transfected with pCMVSPORT•HsPEX16 (panels c and g) and PBDD-01–derived PEX16,
PEX16R176Ter (panels d and h). Cells were stained with antibodies to catalase (panels a–d) and to PMP70 (panels e–h; magnification#600
[bar20 mm]). Note that peroxisomes were restored in c and g but not in d and h. B, Biogenesis of peroxisomal proteins. Cell lysates (2#
cells) were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membrane. Immunoblot analysis was done with rabbit510
anti–3-ketoacyl-CoA thiolase antibody (Tsukamoto et al. 1990). Lane 1, Normal control fibroblasts. Lane 2, PBDD-01 fibroblasts. Lane 3,
PBDD-01 fibroblasts transiently transfected with HsPEX16. Unblackened and blackened arrowheads indicate a larger precursor (P) and mature
form (M) of 3-ketoacyl-CoA thiolase, respectively; dot (7) indicates a nonspecific band.
mozawa et al. 1992b). Normal fibroblasts showed a
punctate staining pattern typical of peroxisomes,
whereas cells from a CG-D patient (PBDD-01) with ZS
showed a diffuse, cytosolic staining indicative of per-
oxisome deficiency (fig. 2A, panels a and b). HsPEX16
expression reestablished the assembly of peroxisomes in
PBDD-01 fibroblasts, which were as numerous as those
in normal cells (fig. 2A, panel c). Assessment by means
of cell staining with antibodies to PTS1 and 3-ketoacyl-
CoA thiolase, a PTS2 protein (data not shown), showed
that peroxisomal protein import was also reestablished.
Peroxisomal remnants, so-called ghosts (Santos et al.
1988), were discernible with anti-PMP70 antibody in
fibroblasts from a PEX2-defective CG-F patient with ZS
(Shimozawa et al. 1992b; fig. 2A, panel e), as reported
for cells from peroxisome-deficient patients of all CGs
so far examined (Santos et al. 1988; Wiemer et al. 1989;
Santos et al. 1992; Wendland and Subramani 1993). In
contrast, consistent with the recent findings by Shimo-
zawa et al. (1998 [in this issue]), peroxisomal ghosts
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Table 1
Complementation Analysis of Patient Fibroblasts and CHO Cell Mutants by HsPEX16
Source of
Patient
Fibroblasts
Peroxisome
Positive
CHO
Mutant
Peroxisome-
Positive Cells Gene
CG-D (PBDD-01) [CG-IX] 19/200 PEX16
CG-A [CG-VIII] )
CG-B [CG-VII] ) PEX10
CG-(C) [CG-IV] ZP92 ) PEX6
CG-(E) [CG-I] ZP107 ) PEX1
CG-(F) [CG-X] Z65 ) PEX2
[CG-II] ZP105 ) PEX5
[CG-III] ZP109 ) PEX12
[CG-VI] )
CG-G )
ZP110 )
ZP114 )
ZP119 )
NOTE.—Patient fibroblasts from five CGs of PBDs (Fujiki 1997)—namely, CGs D (pa-
tient PBDD-01), A, B, and G of Gifu University, Gifu, Japan, and CG-VI of Kennedy-
Krieger Institute, Baltimore—and peroxisome-deficient CHO mutants of eight CGs (Fujiki
1997; Tateishi et al. 1997; Kinoshita et al. 1998)—including PEX6-defective ZP92 (Shi-
mozawa et al. 1992a; Tsukamoto et al. 1995), PEX1-impaired ZP107 (Okumoto et al.
1997; Tamura et al. 1998), PEX2-deficient Z65 (Tsukamoto et al. 1991; Shimozawa et
al. 1992b; Tsukamoto et al. 1994), PEX5-defective ZP105 (Okumoto et al. 1997; Otera
et al. 1998), PEX12-deficient ZP109 (Okumoto et al. 1997; Okumoto and Fujiki 1997;
Okumoto et al. 1998b), and recently isolated ZP119 (Kinoshita et al. 1998)—were trans-
fected with pCMVSPORT•HsPEX16 and examined for peroxisome assembly by immu-
nostaining with antisera to human catalase (in the case of fibroblasts) and rat catalase (in
the case of CHO mutants) at 3 d posttransfection. CGs in parentheses were not used in
this experiment. CGs in brackets indicate U.S. nomenclature; ellipses ()) indicate not
complemented.
were not detected in PBDD-01 fibroblasts, apparently
indicating a defect in peroxisome membrane biogenesis
(fig. 2A, panel f). On transfection of HsPEX16, PMP70-
positive peroxisomes were formed (fig. 2A, panel g), but
the patient PBDD-01–derived PEX16 could not com-
plement peroxisome assembly (fig. 2A, panels d and h;
see below). Taken together, these results demonstrated
that Pex16p morphologically complemented peroxisome
biogenesis in PBDD-01 fibroblasts.
We also investigated the biogenesis of peroxisomal
proteins in CG-D fibroblasts. Peroxisomal 3-ketoacyl-
CoA thiolase is synthesized as a larger, 44-kD precursor
with an amino terminal, cleavable PTS2 (Osumi et al.
1991; Swinkels et al. 1991), and is processed to its final
size, 41 kD, in peroxisomes (Tsukamoto et al. 1990). In
normal fibroblasts, only mature thiolase was detected
(fig. 2B, lane 1), thereby demonstrating rapid processing
of the precursor form. In PBDD-01 cells, only the larger
precursor was found (lane 2), implying a defect of import
and processing activity. When PBDD-01 fibroblasts were
transiently transfected with HsPEX16, both mature and
unprocessed forms of thiolase were seen (fig. 2B, lane
3). The smaller amount of mature thiolase, compared
with that of the precursor, possibly reflects the efficiency
of complementation—that is, ∼10%, at 3 d posttrans-
fection (see table 1). Thus, these results demonstrate that
HsPEX16 can complement the impaired biogenesis of
peroxisomal proteins in PBDD-01 cells.
HsPEX16 was also introduced into fibroblasts from
four other PBD CGs: A, B, and G of Gifu University and
group VI of the Kennedy-Krieger Institute. As expected,
no fibroblasts of these CGs were complemented (table
1). HsPEX16 expression could not restore peroxisomes
in eight CGs of peroxisome-deficient CHO cell mutants,
of which five represented PBD CGs (Tsukamoto et al.
1990; Shimozawa et al. 1992a; Okumoto et al. 1997;
Tateishi et al. 1997; Kinoshita et al. 1998; Otera et al.
1998; table 1). Taken together, these results confirmed
that Pex16p is the peroxisome-biogenesis factor for the
PBD of CG-D.
Mutation Analysis of CG-D Patient PEX16
To determine the dysfunction of PEX16 in patient
PBDD-01, we isolated PEX16 cDNA from fibroblasts
of PBDD-01 and a normal control, by RT-PCR. Sub-
sequent sequencing of cDNA clones from the patient
indicated a CrT point mutation at nucleotide position
526 (with the A of the initiating ATG being 1) in a codon
(CGA) for Arg, resulting in a premature termination at
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Figure 3 Mutation analysis of PEX16 from a CG-D ZS patient. Partial nucleotide sequence and deduced amino acid sequence of PEX16
cDNA isolated from a normal control (left) and from ZS patient PBDD-01 (middle) are shown. A point mutation at nucleotide residue 526
(shaded region) caused a nonsense mutation in PBDD-01 PEX16 (middle). PCR was also done for DNA from PBDD-01 fibroblasts (right). The
nucleotide sequence was determined for the antisense strand (above); its complementary sense sequence is also shown (below).
Figure 4 Intracellular localization of Pex16p. Human Pex16p
tagged with HA at its C-terminus was expressed in wild-type CHO-
K1 cells. Cells were stained with mouse anti-HA antibody (a) and
rabbit anti-PMP70 antibody (b). Rabbit IgG was detected with Texas
Red–labeled goat anti–rabbit IgG antibody (Leinco Technologies). Ar-
rowheads indicate a Pex16p-HA–expressing cell. Note that punctate
structures, peroxisomes, are superposable in panels a and b. Large
spots are apparently unwashed lipofectamine or its debris (magnifi-
cation #630 [bar 20 mm]).
176Arg (fig. 3, left and middle). Of 20 cDNA clones iso-
lated, termed “PEX16R176Ter,” all showed the same
mutation, thereby suggesting a homozygous mutation.
To determine the zygosity of a PEX16R176Ter mutant
allele, genomic PCR was done to amplify the sequence
corresponding to nucleotide residues 471–697 in the
PEX16 ORF. Only a single type of nucleotide sequence
giving rise to the R176Ter mutation was identified in
the PCR products (fig. 3, right), and a 135-bp intron
was found between residues 541 and 542 (data not
shown). The results were interpreted to mean that ZS
patient PBDD-01 was homozygous for the R176Ter mu-
tation. This mutation, as assessed by back transfection
of PEX16R176Ter to PBDD-01 fibroblasts, inactivated
the function of PEX16, which resulted in no formation
of either peroxisomes or peroxisomal membrane vesicles
(fig. 2A, panels d and h). These findings suggest the
importance of the C-terminal half of Pex16p in its bi-
ological activity. It is equally plausible that the trunca-
tion may affect the stability of the expressed Pex16p.
Intracellular Localization of Pex16p
Subcellular localization of Pex16p was determined by
immunofluorescence microscopy following ectopic ex-
pression of Pex16p tagged with the HA epitope at its
C-terminus. HsPEX16HA expression restored peroxi-
some assembly in PBDD-01 fibroblasts, indicating that
C-terminal tagging did not interfere with Pex16p func-
tion, although Pex16p-HA protein was not detected by
use of anti-HA antibody, presumably because of a low
level of expression (data not shown). In HsPEX16HA–
transfected CHO-K1 cells, Pex16p was detected in a
punctate staining pattern (fig. 4A, panel a). The pattern
was superposable on that obtained with anti-PMP70 an-
tibody (fig. 4A, panel b), thereby demonstrating that
Pex16p-HA was localized to peroxisomes. Yarrowia
lipolytica Pex16p was shown to be a peroxisomal pe-
ripheral membrane protein with four putative hydro-
phobic domains (Eitzen et al. 1997). It would be intrigu-
ing to investigate whether human Pex16p, like the yeast
protein, shows intraperoxisomal localization.
Collectively, the data in the present study demonstrate
that dysfunction of PEX16 is responsible for peroxisome
deficiency in CG-D patients with PBDs. Peroxisomal
ghosts have been reported in fibroblasts from peroxi-
some-deficient patients (Santos et al. 1988; Wiemer et
al. 1989; Santos et al. 1992; Wendland and Subramani
1993). In contrast, CG-D fibroblasts are apparently de-
fective in peroxisomal membrane biogenesis, as was the
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case for a CHO mutant ZP119 that we recently char-
acterized (Kinoshita et al. 1998). Pex16p expression re-
stores peroxisome assembly in CG-D cells, evidently in-
dicating that Pex16p is involved in peroxisome assembly,
presumably at the stage of peroxisomal membrane ves-
icle formation. Therefore, Pex16p is the first peroxin that
complements PBD cells morphologically devoid of per-
oxisomal remnants. These results may also suggest that
peroxisomes can form de novo and do not have to arise
from preexisting peroxisomes.
Six mammalian peroxin genes involved in peroxisome
assembly have been isolated either by homology search
of the human EST database or by genetic functional
complementation of CHO cell mutants: PEX1 for CG-
E in Japan (CG-I in the United States; Portsteffen et al.
1997; Reuber et al. 1997; Tamura et al. 1998); PEX2
for CG-F in Japan (Shimozawa et al. 1992b); PEX5 for
CG-II (Dodt et al. 1995; Wiemer et al. 1995; Otera et
al. 1998); PEX6 for CG-C in Japan (Tsukamoto et al.
1995; Fukuda et al. 1996; Yahraus et al. 1996); PEX10
for CG-B in Japan (Okumoto et al. 1998a); and PEX12
for CG-III (Chang et al. 1997; Okumoto and Fujiki
1997; Okumoto et al. 1998b; see also table 1). Thus,
PEX16 is the seventh gene identified as being responsible
for peroxisome-deficiency diseases. PEX7 encoding the
PTS2-receptor was mutated in patients with rhizomelic
chondrodysplasia punctata, in which morphologically
normal peroxisomes are present, but those peroxisomes
are defective in the import of PTS2 proteins (Braverman
et al. 1997; Motley et al. 1997; Purdue et al. 1997). It
is possible that Pex16p functions, through interaction
with other PEX proteins, as the peroxisome-biogenesis
factor in the peroxisomal protein-import processes (Dis-
tel et al. 1996; Fujiki 1997; Subramani 1997; Okumoto
et al. 1998a, 1998b; Tamura et al. 1998). Pex16p may
also be involved in the proliferation of peroxisomes, as
noted in Y. lipolytica (Eitzen et al. 1997).
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